Business context and reporting period
The supplied filing is 180 Life Sciences Corp.’s unaudited Form 10-Q for the three and nine months ended September 30, 2023; it does not appear to be a filing for FORUM MARKETS Inc. 180 Life Sciences is a clinical-stage biotechnology company developing therapies for chronic pain, inflammation and related conditions, with fibrosis/anti-TNF, CBD-derivative and α7nAChR platforms. It reported no revenue.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Operating expenses | $3.54 million | $4.06 million | $12.03 million | $12.26 million |
| Operating loss | $3.54 million | $4.06 million | $12.03 million | $12.26 million |
| Net loss | $10.27 million | $21.49 million | $18.71 million | $16.98 million |
| Basic and diluted loss per share | $(1.29) | $(10.97) | $(3.31) | $(9.49) |
- Q3 R&D expense rose 67% to $1.10 million, including related-party R&D; general and administrative expense fell 29% to $2.43 million. Nine-month R&D rose 39% to $2.82 million, including related-party expense; G&A fell 12% to $9.20 million.
- Q3 net loss included a $9.06 million impairment of in-process R&D, partly offset by a $2.35 million income tax benefit. The prior-year quarter included an $18.87 million goodwill impairment. For the nine-month comparison, lower gains from changes in derivative fair value and the current-year IP R&D impairment contributed to the higher net loss.
- Cash was $2.66 million at September 30, down from $6.97 million at December 31, 2022. Working capital was negative $1.44 million; stockholders’ equity was negative $0.15 million. Nine-month operating cash use was $8.76 million, versus $9.20 million in 2022. Financing provided $4.44 million, principally from April and August equity/warrant offerings, net of offering costs and debt repayments.
- Total loans payable were $0.36 million, including $0.33 million current and $0.02 million noncurrent. Total liabilities were $5.11 million. Gross margin is not applicable given no revenue.
Material changes, outlook and risks
- The company impaired the remaining $9.06 million IP R&D asset to zero in Q3, citing commercialization delays and other impairment indicators. The related deferred tax liability decreased, generating the $2.35 million tax benefit.
- The company raised approximately $3.0 million gross in each of its April and August 2023 offerings. It also amended warrant exercise prices during 2023; the August amendment generated approximately $1.4 million of equity issuance costs. These financings and outstanding warrants create substantial potential dilution.
- Management stated that available financial resources were expected to fund operations only through approximately January 2024 and that monthly cash needs were approximately $650,000. The company identified substantial doubt about its ability to continue as a going concern and expects to seek additional funding, potentially on dilutive or unfavorable terms. Estimated contractual and other cash requirements were approximately $2.5 million for the remainder of 2023 and $27 million for 2024–2027.
- Following an August 2023 meeting, the UK MHRA indicated that a substantially completed Phase 3 trial would be required before a marketing authorization for the company’s Dupuytren’s disease candidate could potentially be granted, extending the anticipated approval and commercialization path. No quantified financial guidance was provided.
- The exhibit list includes a September 22, 2023 Oxford License termination letter. The filing text supplied does not clearly explain the termination’s scope or consequences; its effect on the development pipeline and license rights warrants review.
- Nasdaq notified the company of a minimum bid-price deficiency, with an initial cure deadline of March 5, 2024. It also found the August financing violated shareholder-approval rules; the company intended to submit a compliance plan. The filing also states stockholders’ equity was below Nasdaq’s $2.5 million threshold. Delisting could impair trading liquidity and access to capital.
- Material litigation includes claims against former KBL executives and others, a Tyche dispute in which the court granted the company’s summary-judgment motion but damages remained to be determined, and an ongoing insurance coverage dispute. The company said outcomes are uncertain. The filing reported no liabilities recorded for loss contingencies at September 30.
- Disclosure controls were assessed as ineffective, with a continuing material weakness involving review precision for warrant fair values and IP R&D valuation. Management described remediation steps, but had not concluded the weakness was remediated.
- Clinical, regulatory, manufacturing, financing, intellectual-property and third-party risks remain significant. The company may never obtain approvals, commercialize a product, generate revenue or become profitable.
Most important facts for investors to verify
- Confirm that this is the intended issuer: the filing identifies 180 Life Sciences Corp. (Nasdaq: ATNF/ATNFW), not FORUM MARKETS Inc.
- Review the Oxford License termination letter and determine which rights, programs and obligations it affects.
- Check current cash, burn rate, financing availability and any subsequent developments after the stated January 2024 runway estimate.
- Track Nasdaq compliance plans and status for the bid-price, shareholder-approval and stockholders’ equity requirements.
- Assess the remaining clinical and regulatory path for Dupuytren’s disease, including the MHRA’s Phase 3 requirement.
- Review potential dilution from outstanding warrants, pre-funded warrants, options and future financing needs, as well as the status of significant litigation and the insurance recovery claims.